No Data
Recent 6.3% Pullback Would Hurt Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Insiders
HAOHAI BIOTEC (06826.HK) spent 1.0705 million HKD to repurchase 0.04 million shares on December 20.
Gelonghui reported on December 20 that HAOHAI BIOTEC (06826.HK) announced it spent HKD 1.0705 million to repurchase 0.04 million shares, with a repurchase price of HKD 26.7-26.85 per share. On the same day, the company spent RMB 1.9862 million to repurchase 0.032 million shares, with a repurchase price of RMB 61.94-62.2 per share.
HAOHAI BIOTEC (06826.HK) spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares on December 19.
Gelonghui reported on December 19 that HAOHAI BIOTEC (06826.HK) announced that on December 19, it spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares, with a repurchase price of 26.75-27 Hong Kong dollars per share.
HAOHAI BIOTEC (06826.HK) spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares on December 18.
On December 18, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced that on December 18, it spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares.
HAOHAI BIOTEC (06826.HK) spent 0.766 million HKD to repurchase 0.028 million shares on December 17.
Gelonghui, December 17: HAOHAI BIOTEC (06826.HK) announced that it spent 0.766 million Hong Kong dollars on December 17 to repurchase 0.028 million shares.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Investors Interested In Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Earnings
No Data
